Topiramate + Cognitive Behavioral Therapy + Placebo + Cognitive Behavioral Therapy
Phase 3UNKNOWN 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Cocaine-Related Disorders
Conditions
Cocaine-Related Disorders
Trial Timeline
Oct 1, 2005 → Oct 1, 2012
NCT ID
NCT00249691About Topiramate + Cognitive Behavioral Therapy + Placebo + Cognitive Behavioral Therapy
Topiramate + Cognitive Behavioral Therapy + Placebo + Cognitive Behavioral Therapy is a phase 3 stage product being developed by Johnson & Johnson for Cocaine-Related Disorders. The current trial status is unknown. This product is registered under clinical trial identifier NCT00249691. Target conditions include Cocaine-Related Disorders.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00448825 | Phase 3 | UNKNOWN |
| NCT00249691 | Phase 3 | UNKNOWN |
Competing Products
3 competing products in Cocaine-Related Disorders
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Topiramate | Johnson & Johnson | Phase 2 | 52 |
| quetiapine | AstraZeneca | Approved | 85 |
| AFQ056 + Placebo | Novartis | Phase 2 | 52 |